UY33667A - Compuestos antivirales - Google Patents

Compuestos antivirales

Info

Publication number
UY33667A
UY33667A UY0001033667A UY33667A UY33667A UY 33667 A UY33667 A UY 33667A UY 0001033667 A UY0001033667 A UY 0001033667A UY 33667 A UY33667 A UY 33667A UY 33667 A UY33667 A UY 33667A
Authority
UY
Uruguay
Prior art keywords
antiviral compounds
compounds
hcv
hepatitis
replication
Prior art date
Application number
UY0001033667A
Other languages
English (en)
Inventor
Mark A Matulenko
David A Betebenner
Wagner Rolf
Michael D Tufano
Todd W Rockway
John T Randolph
Christopher E Motter
Clarence J Maring
Allan C Krueger
Warren M Kati
Douglas K Hutchinson
Charles A Flentge
Pamela L Donner
David A Degoey
Gao Yi
Sarris Kathy
Kevin R Woller
Seble H Wagaw
William A Carroll
Daniel D Caspi
Mary E Bellizzi
Charles W Hutchins
Lissa T Nelson
Sachin V Patel
Ryan G Keddy
Tammie K Jinkerson
Liu Dachun
John K Pratt
Jean C Califano
Li Wenke
Original Assignee
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44860553&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UY33667(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US12/903,822 external-priority patent/US20110092415A1/en
Application filed by Abbott Lab filed Critical Abbott Lab
Publication of UY33667A publication Critical patent/UY33667A/es
Priority to UY0001035266A priority Critical patent/UY35266A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4355—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/695—Silicon compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/113—Spiro-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/582—Recycling of unreacted starting or intermediate materials

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Compuestos eficaces para inhibir la replicación del virus de la hepatitis C (?HCV?); procesos de elaboración de tales compuestos, composiciones que los comprenden y métodos de uso de los mismos para tratar una infección por HCV.
UY0001033667A 2010-10-13 2011-10-12 Compuestos antivirales UY33667A (es)

Priority Applications (1)

Application Number Priority Date Filing Date Title
UY0001035266A UY35266A (es) 2010-10-13 2014-01-13 Compuestos antivirales

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US12/903,822 US20110092415A1 (en) 2009-06-11 2010-10-13 Anti-Viral Compounds
US12/964,027 US8921514B2 (en) 2009-06-11 2010-12-09 Anti-viral compounds
US201161446800P 2011-02-25 2011-02-25
US13/100,827 US8937150B2 (en) 2009-06-11 2011-05-04 Anti-viral compounds

Publications (1)

Publication Number Publication Date
UY33667A true UY33667A (es) 2012-04-30

Family

ID=44860553

Family Applications (2)

Application Number Title Priority Date Filing Date
UY0001033667A UY33667A (es) 2010-10-13 2011-10-12 Compuestos antivirales
UY0001035266A UY35266A (es) 2010-10-13 2014-01-13 Compuestos antivirales

Family Applications After (1)

Application Number Title Priority Date Filing Date
UY0001035266A UY35266A (es) 2010-10-13 2014-01-13 Compuestos antivirales

Country Status (28)

Country Link
US (5) US8937150B2 (es)
EP (4) EP2692346B1 (es)
JP (1) JP5834085B2 (es)
KR (2) KR101586215B1 (es)
CN (3) CN106986861A (es)
AR (1) AR083398A1 (es)
AU (1) AU2011316506B2 (es)
BR (1) BR112013005701B1 (es)
CA (1) CA2807847C (es)
CO (1) CO6761348A2 (es)
CY (1) CY2017031I2 (es)
DO (1) DOP2013000078A (es)
EA (2) EA033332B1 (es)
EC (1) ECSP13012622A (es)
FR (1) FR17C1040I2 (es)
GT (1) GT201300093A (es)
LT (1) LTC2692346I2 (es)
LU (1) LUC00038I2 (es)
MX (2) MX344092B (es)
NL (1) NL300901I2 (es)
NO (2) NO2017057I2 (es)
NZ (1) NZ606645A (es)
PE (2) PE20140835A1 (es)
PL (1) PL2692346T3 (es)
SG (1) SG188951A1 (es)
TW (1) TWI419874B (es)
UY (2) UY33667A (es)
WO (1) WO2012051361A1 (es)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012513410A (ja) 2008-12-23 2012-06-14 アボット・ラボラトリーズ 抗ウイルス化合物
US8541424B2 (en) 2008-12-23 2013-09-24 Abbott Laboratories Anti-viral compounds
RU2541571C2 (ru) * 2009-04-15 2015-02-20 Эббви Инк. Противовирусные соединения
US8716454B2 (en) 2009-06-11 2014-05-06 Abbvie Inc. Solid compositions
US9394279B2 (en) * 2009-06-11 2016-07-19 Abbvie Inc. Anti-viral compounds
US8937150B2 (en) 2009-06-11 2015-01-20 Abbvie Inc. Anti-viral compounds
SG171708A1 (en) * 2009-06-11 2011-07-28 Abbott Lab Anti-viral compounds to treat hcv infection
RU2554087C2 (ru) 2009-12-18 2015-06-27 Айденикс Фармасьютикалз, Инк. 5,5-конденсированные ариленовые или гетероариленовые ингибиторы вируса гепатита с
CN102791687B (zh) * 2009-12-18 2015-02-11 北京凯因科技股份有限公司 C型肝炎病毒复制的新型抑制剂
NZ605440A (en) 2010-06-10 2014-05-30 Abbvie Bahamas Ltd Solid compositions comprising an hcv inhibitor
HUE026832T2 (en) * 2010-10-13 2016-07-28 Abbvie Bahamas Ltd Antiviral 1-phenyl-2,5-dibenzimidazol-5-ylpyrrolidine derivative
US8552047B2 (en) 2011-02-07 2013-10-08 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US9546160B2 (en) 2011-05-12 2017-01-17 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US10201584B1 (en) 2011-05-17 2019-02-12 Abbvie Inc. Compositions and methods for treating HCV
WO2013030750A1 (en) 2011-09-01 2013-03-07 Lupin Limited Antiviral compounds
US9034832B2 (en) 2011-12-29 2015-05-19 Abbvie Inc. Solid compositions
CA2857339C (en) * 2011-12-29 2015-11-17 Abbvie Inc. Solid compositions comprising an hcv inhibitor
US9326973B2 (en) 2012-01-13 2016-05-03 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
SG11201404475TA (en) 2012-02-10 2014-08-28 Lupin Ltd Antiviral compounds with a dibenzooxaheterocycle moiety
CN104661662A (zh) * 2012-09-18 2015-05-27 艾伯维公司 治疗丙型肝炎的方法
DK2897611T3 (da) * 2012-09-18 2019-11-04 Abbvie Inc Fremgangsmåder til behandling af hepatitis c
ES2771458T3 (es) 2013-01-31 2020-07-06 Gilead Pharmasset Llc Formulación de combinación de dos compuestos antivirales
US20180042982A1 (en) * 2013-03-14 2018-02-15 Abbvie Inc. Methods for Treating HCV
US11484534B2 (en) 2013-03-14 2022-11-01 Abbvie Inc. Methods for treating HCV
PL2968301T3 (pl) * 2013-03-14 2017-09-29 Abbvie Inc. Kombinacja dwóch środków przeciwwirusowych do leczenia zapalenia wątroby typu C
US20200368229A9 (en) * 2013-03-14 2020-11-26 Abbvie Inc. Methods for Treating HCV
KR101853605B1 (ko) * 2013-03-14 2018-05-03 애브비 인코포레이티드 Hcv 환자 치료용 직접 작용 항바이러스제 및 리바비린의 병용제
US20150023913A1 (en) 2013-07-02 2015-01-22 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
US9717712B2 (en) 2013-07-02 2017-08-01 Bristol-Myers Squibb Company Combinations comprising tricyclohexadecahexaene derivatives for use in the treatment of hepatitis C virus
US9775831B2 (en) 2013-07-17 2017-10-03 Bristol-Myers Squibb Company Combinations comprising biphenyl derivatives for use in the treatment of HCV
PL3650014T3 (pl) 2013-08-27 2022-01-31 Gilead Pharmasset Llc Preparat złożony dwóch związków przeciwwirusowych
EP3043803B1 (en) 2013-09-11 2022-04-27 Emory University Nucleotide and nucleoside compositions and their uses
WO2015103490A1 (en) 2014-01-03 2015-07-09 Abbvie, Inc. Solid antiviral dosage forms
EP3125890A1 (en) * 2014-04-02 2017-02-08 AbbVie Inc. Methods for treating hcv
EP3125889A1 (en) * 2014-04-02 2017-02-08 AbbVie Inc. Methods for treating hcv
JP2017515897A (ja) 2014-05-09 2017-06-15 アッヴィ・インコーポレイテッド 結晶形
US20160090373A1 (en) * 2014-09-29 2016-03-31 Abbvie Inc. Solid forms of anti-viral compounds
WO2016134050A1 (en) 2015-02-18 2016-08-25 Abbvie Inc. Anti-viral compounds
WO2016134058A1 (en) 2015-02-18 2016-08-25 Abbvie Inc. Combinations useful to treat hepatitis c virus
WO2016134054A1 (en) 2015-02-18 2016-08-25 Abbvie Inc. Anti-viral compounds
WO2016134051A1 (en) 2015-02-18 2016-08-25 Abbvie Inc. Anti-viral compounds
WO2016134056A1 (en) 2015-02-18 2016-08-25 Abbvie Inc. Anti-viral compounds
WO2016134053A1 (en) 2015-02-18 2016-08-25 Abbvie Inc. Anti-viral compounds
WO2016134057A1 (en) 2015-02-18 2016-08-25 Abbvie Inc. Anti-viral compounds
GB201506660D0 (en) 2015-04-20 2015-06-03 Cellcentric Ltd Pharmaceutical compounds
GB201506658D0 (en) 2015-04-20 2015-06-03 Cellcentric Ltd Pharmaceutical compounds
JO3637B1 (ar) 2015-04-28 2020-08-27 Janssen Sciences Ireland Uc مركبات بيرازولو- وترايازولو- بيريميدين مضادة للفيروسات rsv
US20160375017A1 (en) 2015-06-26 2016-12-29 Abbvie Inc. Solid Pharmaceutical Compositions for Treating HCV
WO2017023631A1 (en) 2015-08-06 2017-02-09 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
WO2017040766A1 (en) 2015-09-02 2017-03-09 Abbvie Inc. Anti-viral tetrahydrofurane derivatives
KR20180063294A (ko) * 2015-10-07 2018-06-11 닛산 가가쿠 고교 가부시키 가이샤 액정 배향제, 액정 배향막, 및 액정 표시 소자
SG11201808220VA (en) 2016-03-22 2018-10-30 Merck Sharp & Dohme Allosteric modulators of nicotinic acetylcholine receptors
JP7129703B2 (ja) 2016-04-28 2022-09-02 エモリー ユニバーシティー アルキン含有ヌクレオチド及びヌクレオシド治療組成物並びにそれらに関連した使用
BR112019019724A2 (pt) * 2017-03-22 2020-04-14 Chia Tai Tianqing Pharmaceutical Group Co Ltd composto contendo silício para resistência à infecção pelo vírus da hepatite c
GB201706806D0 (en) * 2017-04-28 2017-06-14 Sentinel Oncology Ltd Pharmaceutical compounds
CA2981993A1 (en) * 2017-08-02 2019-02-02 Abbvie Inc. Methods for treating hcv
WO2019046569A1 (en) * 2017-09-01 2019-03-07 Abbvie Inc. METHODS FOR THE TREATMENT OF HCV
TW201932470A (zh) 2017-11-29 2019-08-16 愛爾蘭商健生科學愛爾蘭無限公司 具有抗ｒｓｖ活性之吡唑并嘧啶
KR20200116099A (ko) 2018-01-31 2020-10-08 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 Rsv에 대한 활성을 갖는 시클로알킬 치환 피라졸로피리미딘
EP3765459A1 (en) 2018-03-13 2021-01-20 Shire Human Genetic Therapies, Inc. Substituted imidazopyridines as inhibitors of plasma kallikrein and uses thereof
MA52348A (fr) 2018-04-23 2021-03-03 Janssen Sciences Ireland Unlimited Co Composés hétéroaromatiques ayant une activité contre vrs
WO2020047182A1 (en) * 2018-08-29 2020-03-05 Abbvie Inc. Process for manufacturing pibrentasvir active drug substance
CN113412261A (zh) * 2019-04-08 2021-09-17 四川科伦博泰生物医药股份有限公司 苯并咪唑化合物、其制备方法及其用途
EP4031547B1 (en) 2019-09-18 2024-07-17 Takeda Pharmaceutical Company Limited Plasma kallikrein inhibitors and uses thereof
EP4031245A1 (en) 2019-09-18 2022-07-27 Takeda Pharmaceutical Company Limited Heteroaryl plasma kallikrein inhibitors
CN115594591A (zh) * 2021-06-28 2023-01-13 凯特立斯（深圳）科技有限公司（Cn） 一种催化不对称氢化制备哌仑他韦中间体的方法

Family Cites Families (200)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE75755C (de) 1894-06-14 DAHL & COMP, in Barmen Verfahren zur Darstellung von aromatisch substituirten Amidodinaphtylmethanen.
DE3132020A1 (de) * 1981-08-13 1983-03-03 Basf Ag, 6700 Ludwigshafen N-benzoyl-n'-phenylharnstoffe, verfahren zu ihrer herstellung und ihre verwendung zur bekaempfung von insekten und spinnentieren
IT1227260B (it) 1988-09-30 1991-03-28 Himont Inc Dieteri utilizzabili nella preparazione di catalizzatori ziegler-natta
JPH09504266A (ja) 1993-05-24 1997-04-28 スミスクライン・ビーチャム・コーポレイション 血液調節ペプチド
US5683999A (en) 1995-03-17 1997-11-04 The Dupont Merck Pharmaceutical Company Cyclic urea HIV protease inhibitors
SI9500173B (sl) 1995-05-19 2002-02-28 Lek, Trofazna farmacevtska oblika s konstantnim in kontroliranim sproščanjem amorfne učinkovine za enkrat dnevno aplikacijo
US6037157A (en) 1995-06-29 2000-03-14 Abbott Laboratories Method for improving pharmacokinetics
US5935982A (en) 1997-02-28 1999-08-10 The University Of North Carolina At Chapel Hill Methods of treating retroviral infection and compounds useful therefor
US6235493B1 (en) 1997-08-06 2001-05-22 The Regents Of The University Of California Amino acid substituted-cresyl violet, synthetic fluorogenic substrates for the analysis of agents in individual in vivo cells or tissue
US6369091B1 (en) 1998-05-22 2002-04-09 Avanir Pharmaceuticals Benzimidazole analogs as down-regulators of IgE
US6919366B2 (en) 1998-05-22 2005-07-19 Avanir Pharmaceuticals Benzimidazole derivatives as modulators of IgE
US6911462B2 (en) 1998-05-22 2005-06-28 Avanir Pharmaceuticals Benzimidazole compounds for regulating IgE
IL139828A0 (en) 1998-05-22 2002-02-10 Avanir Pharmaceuticals COMPOUNDS HAVING IgE AFFECTING PROPERTIES
KR100336090B1 (ko) 1998-06-27 2002-05-27 윤승원 오일, 지방산 또는 이들의 혼합물을 함유한 난용성 약물의 고형분산제제
US6387885B1 (en) 1998-08-26 2002-05-14 Abbott Laboratories 3′,3′-N-bis-desmethyl-3′-N-cycloalkyl erythromycin derivatives as LHRH antagonists
US6248363B1 (en) 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
DE19913692A1 (de) 1999-03-25 2000-09-28 Basf Ag Mechanisch stabile pharmazeutische Darreichungsformen, enthaltend flüssige oder halbfeste oberflächenaktive Substanzen
EP1244672B1 (en) 1999-12-21 2005-07-20 Sugen, Inc. 4-substituted 7-aza-indolin-2-ones and their use as protein kinase inhibitors
CA2405521C (en) 2000-04-05 2010-06-29 Schering Corporation Macrocyclic ns3-serine protease inhibitors of hepatitis c virus comprising n-cyclic p2 moieties
DE10026698A1 (de) 2000-05-30 2001-12-06 Basf Ag Selbstemulgierende Wirkstoffformulierung und Verwendung dieser Formulierung
US7065453B1 (en) 2000-06-15 2006-06-20 Accelrys Software, Inc. Molecular docking technique for screening of combinatorial libraries
PT1309591E (pt) 2000-08-14 2007-04-30 Ortho Mcneil Pharm Inc Pirazoles substituídos
US6388093B1 (en) 2001-01-05 2002-05-14 Sun Chemical Corporation Syntheses for preparing 1,4-diketopyrrolo [3,4-c]pyrroles
PT1401825E (pt) 2001-06-11 2009-10-23 Virochem Pharma Inc Compostos e métodos para o tratamento ou para a prevenção de infecções com flavivírus
EP2335700A1 (en) 2001-07-25 2011-06-22 Boehringer Ingelheim (Canada) Ltd. Hepatitis C virus polymerase inhibitors with a heterobicylic structure
RU2286343C2 (ru) 2001-08-10 2006-10-27 Орто-Макнейл Фармасьютикал, Инк. Замещенные пиразолы
WO2003068738A1 (en) 2002-02-11 2003-08-21 Neurocrine Biosciences, Inc. Pyrrole derivatives as ligands of melanocortin receptors
TW200304820A (en) 2002-03-25 2003-10-16 Avanir Pharmaceuticals Use of benzimidazole analogs in the treatment of cell proliferation
JP3925265B2 (ja) 2002-03-25 2007-06-06 コニカミノルタホールディングス株式会社 有機エレクトロルミネッセンス素子及びそれを用いた表示装置
AU2003245453B2 (en) 2002-06-14 2008-08-14 Merck Sharp & Dohme Corp. Mitotic kinesin inhibitors
US7361665B2 (en) 2002-07-09 2008-04-22 Vertex Pharmaceuticals Incorporated Inhibitors of c-Jun N-terminal kinases (JNK) and other protein kinases
AU2003264038A1 (en) 2002-08-12 2004-02-25 Bristol-Myers Squibb Company Combination pharmaceutical agents as inhibitors of hcv replication
KR100482276B1 (ko) * 2002-08-12 2005-04-13 한국과학기술연구원 피롤계 화합물, 그 중합체 및 이들을 이용한 ｅｌ 소자
GB0229518D0 (en) 2002-12-19 2003-01-22 Astrazeneca Ab Chemical compounds
TW200508224A (en) 2003-02-12 2005-03-01 Bristol Myers Squibb Co Cyclic derivatives as modulators of chemokine receptor activity
JP4810427B2 (ja) * 2003-05-22 2011-11-09 アボット・ラボラトリーズ インダゾール、ベンズイソオキサゾールおよびベンズイソチアゾールキナーゼ阻害剤
US8025899B2 (en) 2003-08-28 2011-09-27 Abbott Laboratories Solid pharmaceutical dosage form
JP2007505603A (ja) 2003-09-12 2007-03-15 ヴァーテックス ファーマシューティカルズ、 インコーポレイテッド プロテアーゼ活性および肝障害のための動物モデル
SI1677827T1 (sl) 2003-10-27 2009-06-30 Vertex Pharma Zdravilni sestavek proti virusu hepatitisa c (hcv)
ES2431314T3 (es) * 2004-02-20 2013-11-26 Boehringer Ingelheim International Gmbh Inhibidores de polimerasa vírica
BRPI0401908A (pt) 2004-06-04 2006-01-17 Univ Rio De Janeiro Compostos inibidores de serina protease, processo de obtenção e uso para tratamento de flaviviroses
US7772271B2 (en) 2004-07-14 2010-08-10 Ptc Therapeutics, Inc. Methods for treating hepatitis C
JP5014129B2 (ja) 2004-07-27 2012-08-29 ギリアード サイエンシーズ， インコーポレイテッド イミダゾ［４，５−ｄ］ピリミジン、それらの使用および調製方法
BRPI0514316A (pt) 2004-08-13 2008-06-10 Praecis Pharm Inc métodos e composições para modulação de atividade de receptor de esfingosina-1-fosfato (s1p)
CN101027292A (zh) * 2004-09-24 2007-08-29 阿斯利康(瑞典)有限公司 化合物、含有它们的组合物、其制备方法及其用途
TW200633718A (en) * 2004-12-16 2006-10-01 Applied Research Systems Treatment of hepatitis c in the asian population
EP1844035A1 (en) 2005-02-01 2007-10-17 Wyeth Amino-pyridines as inhibitors of beta-secretase
EP1848692A1 (en) 2005-02-14 2007-10-31 Wyeth AZOLYLACYLGUANIDINES AS ß-SECRETASE INHIBITORS
GB2438802A (en) 2005-02-28 2007-12-05 Univ Rockefeller Structure of the hepatitis C virus NS5A protein
US8143288B2 (en) 2005-06-06 2012-03-27 Bristol-Myers Squibb Company Inhibitors of HCV replication
PE20070099A1 (es) 2005-06-30 2007-02-06 Janssen Pharmaceutica Nv N-heteroarilpiperazinil ureas como moduladores de la amida hidrolasa del acido graso
EP1907398A1 (en) 2005-07-15 2008-04-09 AstraZeneca AB Therapeutic agents
WO2007070600A2 (en) 2005-12-12 2007-06-21 Genelabs Technologies, Inc. N-(5-membered heteroaromatic ring)-amido anti-viral compounds
KR20080075909A (ko) 2005-12-12 2008-08-19 제네랩스 테크놀로지스, 인코포레이티드 Ｎ-(6-원 방향족 환)-아미도 항-바이러스 화합물
WO2007081517A2 (en) 2005-12-21 2007-07-19 Abbott Laboratories Anti-viral compounds
CN102702194A (zh) 2005-12-21 2012-10-03 雅培制药有限公司 抗病毒化合物
WO2007076034A2 (en) 2005-12-21 2007-07-05 Abbott Laboratories Anti-viral compounds
EP1963276B9 (en) 2005-12-21 2012-09-26 Decode Genetics EHF N-linked aryl heteroaryl inhibitors of lta4h for treating inflammation
WO2007082554A1 (en) 2006-01-23 2007-07-26 Istituto Di Ricerche Di Biologia Molecolare P Angeletti Spa Modulators of hcv replication
BRPI0711591A2 (pt) 2006-05-16 2011-11-16 Aegera Therapeutics Inc composto de ligação de domìnio bir da iap
JP2007320925A (ja) 2006-06-02 2007-12-13 Mitsubishi Chemicals Corp トリアリールアミン系化合物並びにそれを用いた電子写真感光体及び画像形成装置
BRPI0712680A2 (pt) 2006-06-08 2012-11-20 Lilly Co Eli antagonistas de receptor de mch
JP5065384B2 (ja) 2006-06-16 2012-10-31 シンジェンタ パーティシペーションズ アクチェンゲゼルシャフト 殺微生物剤として有用なエテニルカルボキサミド誘導体
US20100143499A1 (en) 2006-07-24 2010-06-10 Tetralogic Pharmaceuticals Corporation Dimeric iap inhibitors
US20100056495A1 (en) 2006-07-24 2010-03-04 Tetralogic Pharmaceuticals Corporation Dimeric iap inhibitors
US7659270B2 (en) 2006-08-11 2010-02-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US20100158862A1 (en) 2006-08-11 2010-06-24 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
US8303944B2 (en) 2006-08-11 2012-11-06 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8329159B2 (en) 2006-08-11 2012-12-11 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7745636B2 (en) 2006-08-11 2010-06-29 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7759495B2 (en) 2006-08-11 2010-07-20 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
EP2099778A2 (en) 2006-11-21 2009-09-16 Smithkline Beecham Corporation Amido anti-viral compounds
WO2008070447A2 (en) 2006-11-21 2008-06-12 Smithkline Beecham Corporation Anti-viral compounds
TWI399380B (zh) 2006-12-20 2013-06-21 Abbott Lab 抗病毒化合物
WO2008074450A2 (en) 2006-12-20 2008-06-26 Nicox S.A. Non-peptidic renin inhibitors nitroderivatives
JP5454943B2 (ja) 2007-04-12 2014-03-26 ジョイアント ファーマスーティカルズ、インク． 抗癌剤として有用なｓｍａｃ模倣二量体及び三量体
US7741347B2 (en) 2007-05-17 2010-06-22 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8173696B2 (en) 2007-06-13 2012-05-08 Baylor University Inhibitors of cysteine proteases and methods of use thereof
WO2009003009A1 (en) 2007-06-26 2008-12-31 Enanta Pharmaceuticals, Inc. Substituted pyrrolidine as anti-infectives
CA2695365A1 (en) 2007-08-03 2009-02-12 Schering Corporation Method of treating cxcr3 mediated diseases using heterocyclic substituted piperazines
US8629171B2 (en) 2007-08-08 2014-01-14 Bristol-Myers Squibb Company Crystalline form of methyl ((1S)-1-((25)-2-(5-(4'-(2-((25)-1((2S)-2-((methoxycarbonyl)amino)-3-methylbutanoyl)-2-pyrrolidinyl)-1H-imidazol-2-yl)-1-pyrrolidinyl)carbonyl)-2-methylpropyl)carbamate dihydrochloride salt
US7728027B2 (en) 2007-08-08 2010-06-01 Bristol-Myers Squibb Company Process for synthesizing compounds useful for treating hepatitis C
GB0801199D0 (en) 2008-01-23 2008-02-27 Acal Energy Ltd Fuel cells
WO2009094224A1 (en) 2008-01-25 2009-07-30 Millennium Pharmaceuticals, Inc. Thiophenes and their use as phosphatidylinositol 3-kinase (pi3k) inhibitors
CN102015692A (zh) 2008-02-12 2011-04-13 百时美施贵宝公司 丙型肝炎病毒抑制剂
ES2383388T3 (es) 2008-02-12 2012-06-20 Bristol-Myers Squibb Company Inhibidores del virus de la hepatitis C
US7704992B2 (en) 2008-02-13 2010-04-27 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
NZ587557A (en) 2008-02-13 2012-04-27 Bristol Myers Squibb Co Imidazolyl biphenyl imidazoles as hepatitis c virus inhibitors
US8147818B2 (en) 2008-02-13 2012-04-03 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
JP5750266B2 (ja) 2008-02-28 2015-07-15 アッヴィ・インコーポレイテッド 錠剤およびその調製
US20110117081A1 (en) 2008-05-05 2011-05-19 Aegera Therapeutics, Inc. Functionalized pyrrolidines and use thereof as iap inhibitors
WO2009143361A1 (en) 2008-05-22 2009-11-26 Smithkline Beecham Corporation Amido anti-viral compounds
WO2009155709A1 (en) 2008-06-27 2009-12-30 Aegera Therapeutics Inc. Bridged secondary amines and use thereof as iap bir domain binding compounds
DK2310095T3 (da) 2008-07-22 2012-12-10 Merck Sharp & Dohme Makrocykliske quinoxalinforbindelser som hcv-ns3-protease-inhibitorer
CN102171209A (zh) 2008-08-02 2011-08-31 健泰科生物技术公司 Iap抑制剂
US20120009141A1 (en) 2008-08-07 2012-01-12 Pharmascience Inc. Functionalized pyrrolidines and use thereof as iap inhibitors
US7906655B2 (en) 2008-08-07 2011-03-15 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
UY32099A (es) * 2008-09-11 2010-04-30 Enanta Pharm Inc Inhibidores macrocíclicos de serina proteasas de hepatitis c
US8383094B2 (en) 2008-10-01 2013-02-26 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8946289B2 (en) 2008-11-19 2015-02-03 Duke University Manassatin compounds and methods of making and using the same
JP2010126571A (ja) 2008-11-26 2010-06-10 Toyo Ink Mfg Co Ltd 有機エレクトロルミネッセンス素子材料および有機エレクトロルミネッセンス素子
US8729077B2 (en) 2008-11-28 2014-05-20 Glaxosmithkline Llc Anti-viral compounds, compositions, and methods of use
CA2750577A1 (en) 2008-12-03 2010-06-10 Presidio Pharmaceuticals, Inc. Inhibitors of hcv ns5a
CN104163816A (zh) 2008-12-03 2014-11-26 普雷西迪奥制药公司 Hcv ns5a的抑制剂
JP2012513410A (ja) 2008-12-23 2012-06-14 アボット・ラボラトリーズ 抗ウイルス化合物
US8541424B2 (en) 2008-12-23 2013-09-24 Abbott Laboratories Anti-viral compounds
US8314135B2 (en) 2009-02-09 2012-11-20 Enanta Pharmaceuticals, Inc. Linked dibenzimidazole antivirals
WO2010091413A1 (en) 2009-02-09 2010-08-12 Enanta Pharmaceuticals, Inc. Linked dibenzimidazole derivatives
WO2010096462A1 (en) 2009-02-17 2010-08-26 Enanta Pharmaceuticals, Inc Linked diimidazole derivatives
US8637561B2 (en) 2009-02-17 2014-01-28 Enanta Pharmaceuticals, Inc. Linked diimidazole derivatives
US8394968B2 (en) 2009-02-17 2013-03-12 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8242156B2 (en) 2009-02-17 2012-08-14 Enanta Pharmaceuticals, Inc. Linked dibenzimidazole derivatives
US8420686B2 (en) 2009-02-17 2013-04-16 Enanta Pharmaceuticals, Inc. Linked diimidazole antivirals
US8188132B2 (en) 2009-02-17 2012-05-29 Enanta Pharmaceuticals, Inc. Linked dibenzimidazole derivatives
TWI438200B (zh) 2009-02-17 2014-05-21 必治妥美雅史谷比公司 Ｃ型肝炎病毒抑制劑
WO2010094977A1 (en) 2009-02-23 2010-08-26 Arrow Therapeutics Limited Novel biphenyl compounds useful for the treatment of hepatitis c
CA2753313A1 (en) 2009-02-23 2010-08-26 Presidio Pharmaceuticals, Inc. Inhibitors of hcv ns5a
MY160130A (en) 2009-02-27 2017-02-28 Enanta Pharm Inc Hepatitis c virus inhibitors
US8673954B2 (en) 2009-02-27 2014-03-18 Enanta Pharmaceuticals, Inc. Benzimidazole derivatives
US8426458B2 (en) 2009-02-27 2013-04-23 Enanta Pharmaceuticals, Inc. Hepatitis C Virus inhibitors
US8101643B2 (en) 2009-02-27 2012-01-24 Enanta Pharmaceuticals, Inc. Benzimidazole derivatives
US8507522B2 (en) 2009-03-06 2013-08-13 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
ME02418B (me) 2009-03-27 2016-09-20 Merck Sharp & Dohme Inhibitori replikacije virusa hepatitisa c
CA2756255A1 (en) 2009-03-27 2010-09-30 Presidio Pharmaceuticals, Inc. Substituted bicyclic hcv inhibitors
EP2410843A4 (en) 2009-03-27 2012-08-08 Presidio Pharmaceuticals Inc FUSIONED CORE INHIBITORS OF HEPATITIS C
TWI476190B (zh) 2009-03-30 2015-03-11 必治妥美雅史谷比公司 Ｃ型肝炎病毒抑制劑
US20110237636A1 (en) 2009-03-30 2011-09-29 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
US8796466B2 (en) 2009-03-30 2014-08-05 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
JP5787876B2 (ja) 2009-04-08 2015-09-30 ビーエーエスエフ ソシエタス・ヨーロピアＢａｓｆ Ｓｅ ピロロピロール誘導体、その製造方法及び半導体としての使用
TW201038559A (en) 2009-04-09 2010-11-01 Bristol Myers Squibb Co Hepatitis C virus inhibitors
US8143414B2 (en) 2009-04-13 2012-03-27 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
RU2541571C2 (ru) 2009-04-15 2015-02-20 Эббви Инк. Противовирусные соединения
BRPI1016172A2 (pt) 2009-04-24 2016-04-19 Tibotec Pharm Ltd éteres diarílicos
CA2760205A1 (en) 2009-05-12 2010-11-18 Schering Corporation Fused tricyclic aryl compounds useful for the treatment of viral diseases
AP3622A (en) 2009-05-13 2016-03-02 Gilead Sciences Inc Antiviral compounds
CA2762885A1 (en) 2009-05-29 2010-12-02 Schering Corporation Antiviral compounds composed of three aligned aryl moieties to treat diseases such as hepatitis c
US8138215B2 (en) 2009-05-29 2012-03-20 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
EP2435424B1 (en) 2009-05-29 2015-01-21 Merck Sharp & Dohme Corp. Antiviral compounds composed of three linked aryl moieties to treat diseases such as hepatitis c
US8211928B2 (en) 2009-05-29 2012-07-03 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US9394279B2 (en) * 2009-06-11 2016-07-19 Abbvie Inc. Anti-viral compounds
US8937150B2 (en) 2009-06-11 2015-01-20 Abbvie Inc. Anti-viral compounds
SG171708A1 (en) * 2009-06-11 2011-07-28 Abbott Lab Anti-viral compounds to treat hcv infection
US8221737B2 (en) 2009-06-16 2012-07-17 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
WO2010148006A1 (en) 2009-06-16 2010-12-23 Enanta Pharmaceuticals, Inc. Hepatitis c virus inhibitors
US8609648B2 (en) 2009-07-02 2013-12-17 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
WO2011004276A1 (en) 2009-07-06 2011-01-13 Pfizer Limited Hepatitis c virus inhibitors
JP2012533569A (ja) 2009-07-16 2012-12-27 ヴァーテックス ファーマシューティカルズ、 インコーポレイテッド フラビウイルス感染症を治療又は予防するためのベンゾイミダゾール類似体
CN102471324B (zh) 2009-08-07 2014-12-17 泰博特克药品公司 作为丙型肝炎病毒抑制剂的双苯并咪唑衍生物
AU2010291215A1 (en) 2009-09-03 2012-02-23 Janssen Sciences Ireland Uc Bis-benzimidazole derivatives
EP2473056A4 (en) 2009-09-04 2013-02-13 Glaxosmithkline Llc CHEMICAL COMPOUNDS
US8759332B2 (en) 2009-09-11 2014-06-24 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
US8815928B2 (en) 2009-09-11 2014-08-26 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
US8822700B2 (en) 2009-09-11 2014-09-02 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
EP2475256A4 (en) 2009-09-11 2013-06-05 Enanta Pharm Inc HEPATITIS C-VIRUS HEMMER
US8927709B2 (en) 2009-09-11 2015-01-06 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
US8703938B2 (en) 2009-09-11 2014-04-22 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
EP2475254A4 (en) 2009-09-11 2013-05-22 Enanta Pharm Inc HEPATITIS C-VIRUS HEMMER
WO2011050146A1 (en) 2009-10-23 2011-04-28 Glaxosmithkline Llc Chemical compounds
UA108211C2 (uk) 2009-11-04 2015-04-10 Янссен Рід Айрленд Бензімідазолімідазольні похідні
US20110269956A1 (en) 2009-11-11 2011-11-03 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
US20110274648A1 (en) 2009-11-11 2011-11-10 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
US20110281910A1 (en) 2009-11-12 2011-11-17 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
US20120276047A1 (en) 2009-11-25 2012-11-01 Rosenblum Stuart B Fused tricyclic compounds and derivatives thereof useful for the treatment of viral diseases
MY179840A (en) 2009-12-04 2020-11-18 National Health Res Inst Proline derivatives
EP2512480A4 (en) 2009-12-14 2013-05-15 Enanta Pharm Inc HEPATITIS C-VIRUS HEMMER
US8377980B2 (en) 2009-12-16 2013-02-19 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
CN102791687B (zh) 2009-12-18 2015-02-11 北京凯因科技股份有限公司 C型肝炎病毒复制的新型抑制剂
RU2554087C2 (ru) 2009-12-18 2015-06-27 Айденикс Фармасьютикалз, Инк. 5,5-конденсированные ариленовые или гетероариленовые ингибиторы вируса гепатита с
CA2785488A1 (en) 2009-12-22 2011-07-21 Merck Sharp & Dohme Corp. Fused tricyclic compounds and methods of use thereof for the treatment of viral diseases
JP2013515746A (ja) 2009-12-24 2013-05-09 ヴァーテックス ファーマシューティカルズ、 インコーポレイテッド フラビウイルス感染症の治療又は予防のための類似体
US8362020B2 (en) 2009-12-30 2013-01-29 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
WO2011091446A1 (en) 2010-01-22 2011-07-28 Glaxosmithkline Llc Chemical compounds
CA2787309A1 (en) 2010-01-25 2011-07-28 Enanta Pharmaceuticals, Inc. Hepatitis c virus inhibitors
JP2013518062A (ja) 2010-01-28 2013-05-20 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃ型肝炎阻害化合物
US8178531B2 (en) 2010-02-23 2012-05-15 Enanta Pharmaceuticals, Inc. Antiviral agents
KR20120124495A (ko) 2010-03-04 2012-11-13 이난타 파마슈티칼스, 인코포레이티드 Ｈｃｖ 복제의 억제제로서의 조합 제약 작용제
BR112012022125A2 (pt) 2010-03-09 2016-11-01 Merck Sharp & Dhme Corp composto, sal de dicloridrato, composição farmacêutica, uso do composto, e, método para tratar um paciente
MX2012010918A (es) 2010-03-24 2013-01-18 Vertex Pharma Analogos para el tratamiento o prevencion de infecciones por flavivirus.
TW201141857A (en) 2010-03-24 2011-12-01 Vertex Pharma Analogues for the treatment or prevention of flavivirus infections
WO2011119858A1 (en) 2010-03-24 2011-09-29 Vertex Pharmaceuticals Incorporated Analogues for the treatment or prevention of flavivirus infections
EP2550278A1 (en) 2010-03-24 2013-01-30 Vertex Pharmaceuticals Incorporated Analogues for the treatment or prevention of flavivirus infections
WO2011127350A1 (en) 2010-04-09 2011-10-13 Enanta Pharmaceuticals, Inc. Hepatitis c virus inhibitors
US20110312996A1 (en) 2010-05-17 2011-12-22 Intermune, Inc. Novel inhibitors of hepatitis c virus replication
WO2011150243A1 (en) 2010-05-28 2011-12-01 Presidio Pharmaceuticals, Inc. Inhibitors of hcv ns5a
WO2011153396A1 (en) 2010-06-04 2011-12-08 Enanta Pharmaceuticals, Inc Hepatitis c virus inhibitors
WO2011156543A2 (en) 2010-06-09 2011-12-15 Presidio Pharmaceuticals, Inc. Inhibitors of hcv ns5a protein
NZ605440A (en) 2010-06-10 2014-05-30 Abbvie Bahamas Ltd Solid compositions comprising an hcv inhibitor
US8822520B2 (en) 2010-09-22 2014-09-02 Presidio Pharmaceuticals, Inc. Substituted bicyclic HCV inhibitors
CN103249730A (zh) 2010-09-24 2013-08-14 百时美施贵宝公司 丙型肝炎病毒抑制剂
RU2013119607A (ru) 2010-09-29 2014-11-10 Мерк Шарп Энд Домэ Корп. Полициклические гетероциклические соединения и способы их применения для лечения вирусных заболеваний
WO2012040924A1 (en) 2010-09-29 2012-04-05 Merck Sharp & Dohme Corp. Fused tetracyclic heterocycle compounds and methods of use thereof for treatment of viral diseases
CA2811662A1 (en) 2010-09-29 2012-04-05 Merck Sharp & Dohme Corp. Tetracyclic indole derivatives for treating hepatitis c virus infection
TWI471670B (zh) 2010-09-29 2015-02-01 Au Optronics Corp 液晶顯示面板
WO2012040923A1 (en) 2010-09-29 2012-04-05 Merck Sharp & Dohme Corp. Tetracyclic indole derivatives and methods of use thereof for the treatment of viral diseases
EP2621932A4 (en) 2010-09-29 2014-03-26 Merck Sharp & Dohme TETRACYCLIC HETEROCYCLUS COMPOUNDS FOR THE TREATMENT OF HEPATITIS C VIRUS INFECTIONS
WO2012050848A1 (en) 2010-09-29 2012-04-19 Schering Corporation Fused tetracycle derivatives and methods of use thereof for the treatment of viral diseases
CN103189371B (zh) 2010-11-04 2015-04-01 施万生物制药研发Ip有限责任公司 丙型肝炎病毒抑制剂
KR20190140486A (ko) 2010-11-17 2019-12-19 길리애드 파마셋 엘엘씨 항바이러스 화합물
RU2452735C1 (ru) 2010-11-30 2012-06-10 Александр Васильевич Иващенко Замещенные азолы, противовирусный активный компонент, фармацевтическая композиция, способ получения и применения
WO2012087976A2 (en) 2010-12-21 2012-06-28 Intermune, Inc. Novel inhibitors of hepatitis c virus replication

Also Published As

Publication number Publication date
NZ606645A (en) 2014-09-26
WO2012051361A1 (en) 2012-04-19
LTPA2017033I1 (lt) 2017-11-10
BR112013005701B1 (pt) 2022-05-10
EP3438106A1 (en) 2019-02-06
JP5834085B2 (ja) 2015-12-16
BR112013005701A2 (pt) 2020-10-13
CN104193729A (zh) 2014-12-10
SG188951A1 (en) 2013-05-31
KR101831154B1 (ko) 2018-02-26
US10039754B2 (en) 2018-08-07
US9586978B2 (en) 2017-03-07
US20170157104A1 (en) 2017-06-08
PE20140038A1 (es) 2014-02-20
NO2017057I1 (no) 2017-11-10
MX2020002151A (es) 2020-07-13
US10028937B2 (en) 2018-07-24
US20120004196A1 (en) 2012-01-05
EA201390538A1 (ru) 2014-02-28
FR17C1040I2 (fr) 2018-11-16
NO2017057I2 (no) 2018-11-26
MX344092B (es) 2016-12-05
LUC00038I1 (es) 2017-10-12
AR083398A1 (es) 2013-02-21
DOP2013000078A (es) 2018-04-30
UY35266A (es) 2015-07-31
CO6761348A2 (es) 2013-09-30
EP2692346B1 (en) 2015-12-02
FR17C1040I1 (es) 2017-08-12
TW201238948A (en) 2012-10-01
CN103153988A (zh) 2013-06-12
US20190015402A1 (en) 2019-01-17
KR20140143152A (ko) 2014-12-15
EA024100B1 (ru) 2016-08-31
KR101586215B1 (ko) 2016-01-18
ECSP13012622A (es) 2013-07-31
CA2807847C (en) 2016-09-20
CY2017031I1 (el) 2018-04-04
EP2692346A1 (en) 2014-02-05
NL300901I2 (nl) 2017-11-16
EP2627651A1 (en) 2013-08-21
PL2692346T3 (pl) 2016-05-31
CN103153988B (zh) 2014-07-09
EA033332B1 (ru) 2019-09-30
CN106986861A (zh) 2017-07-28
CY2017031I2 (el) 2018-04-04
US20170157105A1 (en) 2017-06-08
AU2011316506A1 (en) 2013-02-21
LTC2692346I2 (lt) 2021-11-10
AU2011316506B2 (en) 2014-06-12
EA201301158A1 (ru) 2014-07-30
TWI419874B (zh) 2013-12-21
GT201300093A (es) 2014-04-29
LUC00038I2 (es) 2017-12-13
US8937150B2 (en) 2015-01-20
EP2692726A1 (en) 2014-02-05
MX2013004150A (es) 2013-09-02
PE20140835A1 (es) 2014-08-15
KR20140032338A (ko) 2014-03-14
JP2013539791A (ja) 2013-10-28
US20150087618A1 (en) 2015-03-26
NO2021039I1 (no) 2021-09-16
CA2807847A1 (en) 2012-04-19

Similar Documents

Publication Publication Date Title
UY35266A (es) Compuestos antivirales
DOP2013000185A (es) Compuestos antivirales
CL2015003615A1 (es) Nucleósidos sustituidos, nucleótidos y análogos de los mismos.
CL2014000612A1 (es) Compuestos derivados de prolinas macrociclicas, inhibidores de las proteasas de serina del virus de la hepatitis c (vhc); composicion farmaceutica que los comprende; y su uso para tratar una infeccion viral tal como la infeccion por el virus de la hepatitis c (vhc).
CL2018001207A1 (es) Compuesto de 7-(tiazol-5-il)pirrolopirimidina como agonista de tlr7
CL2016000381A1 (es) Compuestos antivirales
CL2016000493A1 (es) Inhibidores de polimerasa hcv.
CL2016000805A1 (es) Nucleósidos sustituidos, nucleótidos y análogos de los mismos.
CO6761335A2 (es) Inhibidores del virus de la hepatitis c
CL2016001120A1 (es) Compuestos derivados de pirrolo1,2-f1,2,4triazina ,composición farmacéutica que los comprende y su uso en el tratamiento de una infección por virus sincicial compuestos intermediarios. pct
CL2014003634A1 (es) Inhibidores del virus de la hepatitis c
CL2012001959A1 (es) Compuestos derivados del acido tiofeno-2-carboxilico, inhibidores de virus flaviviridae; composicion farmaceutica que los comprende; y su uso para el tratamiento de una infeccion viral por flaviviridae.
CL2012002057A1 (es) Compuestos macrociclicos sustituidos, como inhibidores del virus de la hepatitis c; proceso de preparacion de dichos compuestos; composicion farmaceutica que los comprende, utiles como agente antivirales.
CL2012000573A1 (es) Compuestos derivados de bifenil-pirrolidinil-imidazol; composicion farmaceutica que los comprende; su uso en el tratamiento de una infeccion viral por hcv.
ECSP11011310A (es) Análogos carba - nucleósido para tratamiento antiviral
CO6700883A2 (es) Inhibidores del virus de la hepatitis c
CR20120440A (es) Compuestos policìclicos heterocìclicos se puede utilizar como inhibidores eficaces para virus de la hepatitis c
CL2014001110A1 (es) Compuestos derivados de piperazin-piridin-bifenil-imidazol-pirrolidinas sustituidas, inhibidores de la replicacion del virus de la hepatitis c (hcv); composicion farmaceutica que los comprende; proceso para preparar un compuesto; metodo para tratar una infeccion del virus hcv; y uso para tratar una infeccion del virus hcv.
CL2015001971A1 (es) Compuestos tetracíclicos sustituidos con heterociclo y métodos de uso de los mismos para el tratamiento de enfermedades víricas.
UY34066A (es) Inhibidores del virus de la hepatitis c
CL2015003358A1 (es) Compuestos derivados de nucleósidos 4'-azido-3'-desoxi-3'-fluoro sustituidos; composición farmacéutica que comprende a dichos compuestos y el uso de los mismos para tratar una infección del virus de la hepatitis c (hcv).
CL2016000300A1 (es) Métodos terapéuticos
UY34420A (es) ?métodos de tratamiento del virus de la hepatitis c con que de gs-7977 y ribavirina, composiciones y usos"
GT201100241A (es) Proceso para preparar compuestos antivirales
CL2015003752A1 (es) Inhibidores de replicación viral, su proceso de preparación y sus uso terapeutico

Legal Events

Date Code Title Description
110 Patent granted

Effective date: 20180924